Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Safety and efficacy of glasdegib for R/R AML

Andrius Žučenka • 10 Jun 2022
EHA 2022
Acute Myeloid Leukemia Leukemia Cytarabine Glasdegib

Andrius Žučenka, PhD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the safety and efficacy of glasdegib for relapsed/refractory (R/R) acute myeloid leukemia (AML). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Andrius Žučenka

ARCHIVE conditioning enables direct-to-transplant strategy in high-risk AML
3:16
ARCHIVE conditioning enables direct-to-transplant strategy in high-risk AML
Andrius Žučenka • 14 Jun 2026
Revumenib after transplant shows promise in KMT2A-rearranged and NPM1-mutated AML
2:57
Revumenib after transplant shows promise in KMT2A-rearranged and NPM1-mutated AML
Andrius Žučenka • 14 Jun 2026
Venetoclax combinations show high remission rates in FLT3- and IDH1-mutated AML
3:57
Venetoclax combinations show high remission rates in FLT3- and IDH1-mutated AML
Andrius Žučenka • 14 Jun 2026
ARCHIVE conditioning for upfront alloSCT in active AML and high-risk MDS-IB2
5:59
ARCHIVE conditioning for upfront alloSCT in active AML and high-risk MDS-IB2
Andrius Žučenka • 6 Jan 2026

Related Videos

How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
4:56
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
Stephan Stilgenbauer • 16 Oct 2026
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
1:22
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
Marta Coscia • 16 Oct 2026
The content of VJHemOnc is intended for healthcare professionals